On Tuesday, March 23, 2021, it was reported that Pfizer, Inc. has begun human safety testing regarding a pill that would treat COVID-19 during first signs of illness.
The drug, code-named as PF-07321332, is a protease-inhibitor, meaning it binds to protease enzymes to prevent viral replication.
Because it is in pill form, it could be administered and taken outside of hospital grounds.
Mikael Dolsten, the company’s Chief Scientific Officer, said “this is really a potential game changer.”
This trial is occurring simultaneously as Pfizer’s other drug, an intravenous treatment which is administered to hospitalized patients.
Specific details of the antiviral pill are not available yet, but the company plans to share more data at the Spring American Chemical Society meeting on April 6, 2021.
Register for our newsletter.